Specifically, the c‐Abl inhibitors bafetinib (aka INNO‐406), radotinib and nilotinib block inactivation of parkin by c‐Abl and protect against neurotoxicity in mouse models of PD.61, 67, 68, 69. The gene discussed is ABL1; the disease is Parkinson disease.